General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Noubar Afeyan Sells 20000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock | news.google.com • |
Letko Brosseau & Associates Inc. Invests $31.77 Million in Moderna, Inc. (NASDAQ:MRNA) | news.google.com • |
Stephen Hoge Sells 341 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock | news.google.com • |
Moderna, Inc. (MRNA) Bernstein's 40th Annual Strategic Decisions Conference (Transcript) | seekingalpha.com • |
Noubar Afeyan Sells 20,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock | news.google.com • |
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2023-11-02 | 2023-09 | -2.01 | N/A | N/A | N/A |
2023-11-02 | 2023-09 | -2.01 | -1.39 | 0.62 | 30.85% |
2023-08-03 | 2023-06 | -3.84 | -3.62 | 0.22 | 5.73% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-21 | AFEYAN NOUBAR BOGHOS | Director | 11.65M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-05-28 | HOGE STEPHEN | President | 1.63M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
$MRNA Moderna has already started to prepare for rapid acceleration of its manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and of expected benefit. We are working around-the-clock to make sure a vaccine is available as quickly and as broadly as possible. We will continue to work together, with government, industry and other third parties to enable the best chance for success.
$MRNA Moderna has already started to prepare for rapid acceleration of its manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and of expected benefit. We are working around-the-clock to make sure a vaccine is available as quickly and as broadly as possible. We will continue to work together, with government, industry and other third parties to enable the best chance for success.
$MRNA The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmac... https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-141602648.html?soc_src=social-sh&soc_trk=tw via @YahooFinance
$MRNA So, who are the developers leading the race for the highly sought-after vaccine?ModernaThe first dose of the mRNA-1273 coronavirus vaccine, developed by the US National Institutes of Health (NIH) and Moderna’s infectious disease research team, was given to the first participant in their Phase 1 study on March 16. The trial of the vaccine, built on previous studies of SARS and MERS, is intended to provide data on the safety and immunogenicity of the vaccine, and is expected to enroll 45 healthy adult volunteers over six weeks.
$MRNA Moderna notched a 24% increase after it revealed that the first participant in the Phase 1 trial of its mRNA-1273 COVID-19 candidate had been dosed. The National Institute of Allergy and Infectious Diseases (NIAID) is currently running the trial in Seattle, and a grant awarded to the company by the Coalition for Epidemic Preparedness Innovations (CEPI) is being used to fund the Phase 1 manufacturing material. In an effort to advance the vaccine candidate as quickly as possible, MRNA has already started to prepare for a possible Phase 2 trial, initiating the manufacturing of Phase 2 material.
I am thinking MRNA will be like BLPH that when you wake it is already up by $20..
$MRNA MODERNA NEWS: Meanwhile, as SARS-CoV-2, the virus responsible for COVID-19, continues to spread globally, Needham analyst Alan Carr highlighted that Moderna and Gilead (GILD) have the most advanced drug and vaccine programs in development, respectively. Under the FDA's Emergency Use Authorization, the analyst believes a drug treatment could become available this year and a vaccine in 2021. Results from two Chinese trials evaluating remdesivir, a Gilead drug initially developed for another coronavirus, are expected to be announced next month, he added, noting that clinical testing of the first vaccine for COVID-19, Moderna's mRNA-1273, began this week and results may be available in June.
$MRNA MODERNA NEWS: Meanwhile, as SARS-CoV-2, the virus responsible for COVID-19, continues to spread globally, Needham analyst Alan Carr highlighted that Moderna and Gilead (GILD) have the most advanced drug and vaccine programs in development, respectively. Under the FDA's Emergency Use Authorization, the analyst believes a drug treatment could become available this year and a vaccine in 2021. Results from two Chinese trials evaluating remdesivir, a Gilead drug initially developed for another coronavirus, are expected to be announced next month, he added, noting that clinical testing of the first vaccine for COVID-19, Moderna's mRNA-1273, began this week and results may be available in June.
I am not sure what to do to my profits if this one got approved.